On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved the inaugural blood test designed to assist in diagnosing Alzheimer's disease. This groundbreaking test identifies amyloid plaques, a key indicator of Alzheimer's, by analyzing a blood sample, offering a less invasive option compared to current diagnostic methods. The approval signifies a significant advancement in Alzheimer's detection and could potentially revolutionize the diagnostic process for the 5.8 million Americans currently living with this condition.